PPARG and endothelial dysfunction: PPARα and PPARγ mRNA are greater in young and adult SHR mesenteric arteries compared to WKY (but not in other tissues) [91], and thizaolidinedione PPARγ agonists attenuated remodeling and endothelial dysfunction in mesenteric resistance arteries in response to angiotensin II [92] or endothelin-1 [93].